Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Transactional Outsourcing and Strategic Partnerships: An Insider’s Perspective


Click the above image to expand the infographic!

Share this!

October 1, 2015 | by Sarah Massey

As the pharmaceutical industry moves away from an era of blockbuster drug development and into the presently struggling economy, there is more and more pressure on pharmaceutical companies to cut costs and get the most out of their R&D dollars. In the current age of so-called ‘patent cliffs’ – when one drug going off patent could trigger a dramatic decrease in revenue – pharmaceutical companies are increasingly seeking out strategic partnerships, as opposed to one-off transactional outsourcing of vendors.

But practically, what is the distinction between the two types of collaboration – both of which are aimed towards bringing a drug to market? The differences between transactional outsourcing and strategic partnership formation will be discussed in the context of pharmaceutical company collaborations with contract manufacturing organizations (CMOs).

Strategic partnerships benefit both the pharmaceutical developer and the contract manufacturing organization. By working on a longer-term, complex, symbiotic relationship, contract manufacturing organizations and pharmaceutical companies can both benefit from cost savings, as well as shared resources and mutual growth. Providing each company’s culture fits in well with the others – and a solid line of communication and transparency is established – strategic partnerships can be incredibly successful.

According to The Nice Insight 2015 industry survey, the top three factors that are important to pharmaceutical developers – when choosing a contract manufacturing organization to partner with – were:

  1. Financial stability of the organization
  2. Track record/history of success
  3. Experience (operational/methodological/therapeutic).

Despite the clear benefits of strategic partnerships, a report produced by the CMO Council in 2014, found that over half of all strategic partnerships fail. To understand the benefits – and the common challenges – associated with strategic partnerships, I spoke with Richard Fazackerley, Technical Director, Aesica Pharmaceuticals, who will be speaking in more detail about strategic partnerships in a webinar on October 5th.

What are some common motivators for seeking a strategic partnership, over a transactional relationship?

As the life cycle for drug development can go a very long time – 10 to 15 years, if you’re starting from early research to commercialization – the motivator really is that long-term partnership from the very beginning. This is based on the evolution of not just value creation, but using expertise. Rather than transactional relationships, it is really looking beyond that and acknowledging that this is going to be a long strategic journey and therefore, you need a partner who can add value throughout the different phases. It is a recognition that a short-term transactional relationship doesn’t have as many of the advantages of a longer-term, deeper, strategic relationship could have, in terms of both parties benefitting.

What do you think is the biggest advantage of strategic partnerships?

This biggest advantage is the very nature [of strategic partnerships] – unlike a transactional relationship, a strategic partnership has much more built-in flexibility. It is much more adaptive and it adds a much wider depth of service and learning opportunities to both parties.

What you get with a strategic partnership is something that doesn’t just focus on delivering what’s payed for, you get value in many different ways. It is a two-way process so you not only get value, but you share risk. You can learn, balance capabilities, and find ways to access capabilities that you didn’t have, or maybe didn’t know you needed.

At what stage in a drug’s lifecycle is strategic partnership formation the most beneficial?

There is no single stage; a strategic partnership can be undertaken from the very beginning – in early stages of drug development – irrespective of the size [of the company]. Small- to medium-sized companies can benefit from a number of advantages; they can leverage capabilities and capacities early on.

Strategic partnerships can also give smaller companies the advantage. Rather than having people look at them in terms of value of a single product, a strategic partnership can be a longer-term relationship over many different projects. From early stage development, commercialization, or the launch phase, right through to the end of the life cycle of a product. A strategic partnership – at the highest level – allows you to operate at all stages and adapt throughout the life cycle, but also leverage the capabilities of both parties.

What are some common challenges when building successful strategic partnerships?

I think the key is to recognize that it’s a long-term relationship – by this we’re talking about years or decades, rather than the short-term. The first [challenge] is impatience – you want all the benefits today, rather than build it.

It is a bit like a marriage – it is a commitment over the long-term to build and learn, so you have to put the effort in. You need to recognize there is going to be a lot of time and effort over the life cycle of the product, and the life cycle of the partnership.

What you don’t want to do is get pulled into being impatient and wanting quick results, or focusing on financial reward. Clearly finances are very important, but sometimes you miss the benefit of some of the other forms of value that can be created in a strategic partnership. Transactional relationships focus on financial aspects and delivery, whereas a strategic partnership is much broader and deeper – value in that context can be much different than simply measurable financial aspects.

Read Page 2



Using Strategic Partnership for Value Creation from Early Stage Development to Manufacture

The Use of High Resolution Accurate Mass Spectrometry

Keywords: Outsourcing, Strategic Partnership, Contract Manufacturing Organization



Share this with your colleagues!

> Insights Into The Emerging Health Monitoring Medical Device Market

September 24, 2015 - To get an insider’s perspective on where the health monitoring medical device industry is heading, and how these devices could improve outcomes for clinical trials, I spoke with Deepak Prakash, Global Director of Marketing, Digital Health, for Vancive Medical Technologies.

> Precision Medicine and the Paradigm Shift In The Development of Novel Cancer Therapies

September 17, 2015 - To further understand how the paradigm shift in cancer research, diagnosis and treatment will affect how drugs are developed and clinical trials are conducted in Canada, I spoke to Dr. Sian Bevan, director of research for the Canadian Cancer Society.

> Medical Device Innovation: Blurring the Lines Between Medical Necessity and Personal Accessory

September 9, 2015 - As sales of wearable medical monitors rise, and healthy, average consumers increasingly look for high-tech gadgets to monitor their health, device manufacturers are developing technology which can be marketed to both healthy individuals as well as those with specific medical conditions.

Recent Medical Applications of 3-D Printing and the Future of Medical Device Manufacture

September 2, 2015 - While the use of 3-D printers in the pharmaceutical industry is still in its infancy, three-dimensional printing technology has been used for other applications such as medical device manufacture and improvements in research tools available for drug testing.

Printing Your Prescription: How 3-D Printing Technology is Affecting the Pharmaceutical Industry

August 26, 2015 - In the wake of the FDA’s first approved 3-D printed drug – which happened earlier this year – and the promise of three others in the works, experts are predicting that the future of the pharmaceutical industry lies in the development of printable drug products.

Are There Adequate Alternatives to Animal Testing?

August 19, 2015 - Three promising in vitro and in silico technologies including, Modular Immune in vitro Construct (MIMIC), Organ-on-a-Chip and Computer Models of Adverse Drug Reactions, which could reduce the need for animals in research, are reviewed in more detail.


Copyright © 2016-2017 Honeycomb Worldwide Inc.